Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome

European Journal of Clinical Investigation

Volumn 42, Issue 3, 2012, Pages 321-328

  Lajunen, Taina K ^a   Purhonen, Anna Kaisa ^a   Haapea, Marianne ^a   Ruokonen, Aimo ^b   Puukka, Katri ^b   Hartikainen, Anna Liisa ^a   Savolainen, Markku J ^a   Morin Papunen, Laure ^a   Tapanainen, Juha S ^a   Franks, Stephen ^c   Järvelin, Marjo Riitta ^a,d   Herzig, Karl Heinz ^a,e  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adipose tissue; Cytokines; Inflammation; Obesity; Polycystic ovary syndrome; Visfatin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; HORMONE; LIPID; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TESTOSTERONE;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINLAND; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIRSUTISM; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LEUKOPENIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC DISORDER; METABOLIC PARAMETERS; MULTICENTER STUDY; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; SOCIAL STATUS; SOUTH KOREA; SYMPTOM; TESTOSTERONE BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY; WAIST CIRCUMFERENCE;

ADIPOSE TISSUE; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; POLYCYSTIC OVARY SYNDROME; REGRESSION ANALYSIS; WAIST CIRCUMFERENCE;

EID: 84856570715     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02586.x     Document Type: Article

References (40)

1. Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril 2006;86(Suppl. 1):S7-8.
2. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000;15:1266-74.
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9.
4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
5. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685-97.
6. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
7. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Blüher M, Stumvoll M et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 2008;115:13-23.
8. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58.
9. Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 2007;88:401-5.
10. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295-9.
11. Carmina E, Bucchieri S, Mansueto P, Rini G, Ferin M, Lobo RA. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil Steril 2009;91:1332-5.
12. Yildiz BO, Bozdag G, Otegen U, Harmanci A, Boynukalin K, Vural Z et al. Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS. Reprod Biomed Online 2010;20:150-5.
13. Gen R, Akbay E, Muslu N, Sezer K, Cayan F. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol 2009;25:241-5.
14. Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 2007;22:1824-9.
15. Ozkaya M, Cakal E, Ustun Y, Engin-Ustun Y. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril 2010;93:880-4.
16. Panidis D, Farmakiotis D, Rousso D, Katsikis I, Delkos D, Piouka A et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med 2008;19:406-12.
17. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 2006;91:5022-8.
18. Rantakallio P. Groups at risk in low birth weight infants and perinatal mortality. Acta Paediatr Scand 1969;58:5-71.
19. Taponen S, Ahonkallio S, Martikainen H, Koivunen R, Ruokonen A, Sovio U et al. Prevalence of polycystic ovaries in women with self-reported symptoms of oligomenorrhoea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. Hum Reprod 2004;19:1083-8.
20. Taponen S, Martikainen H, Järvelin MR, Sovio U, Laitinen J, Pouta A et al. Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab 2004;89:2114-8.
21. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2.
22. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
23. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;113:1318-27.
24. Bo S, Ciccone G, Baldi I, Gambino R, Mandrile C, Durazzo M et al. Plasma visfatin concentrations after a lifestyle intervention were directly associated with inflammatory markers. Nutr Metab Cardiovasc Dis 2009;19:423-30.
25. Reimann M, Ziemssen T, Huisman HW, Schutte R, Malan L, Van Rooyen JM et al. Ethnic-specific correlations of visfatin with circulating markers of endothelial inflammation and function. Obesity (Silver Spring) 2009;17:2210-5.
26. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 2007;67:796-800.
27. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007;115:972-80.
28. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-7.
29. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007;92:666-72.
30. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009;71:202-7.
31. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1198-201.
32. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007;30:323-6.
33. Zwirska-Korczala K, Sodowski K, Konturek SJ, Kuka D, Kukla M, Brzozowski T et al. Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. J Physiol Pharmacol 2008;59(Suppl. 2):161-78.
34. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21:1426-31.
35. Plati E, Kouskouni E, Malamitsi-Puchner A, Boutsikou M, Kaparos G, Baka S. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil Steril 2010;94:1451-6.
36. Taponen S, Martikainen H, Järvelin MR, Laitinen J, Pouta A, Hartikainen AL et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab 2003;88:141-7.
37. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007;92:4783-91.
38. Retnakaran R, Youn BS, Liu Y, Hanley AJ, Lee NS, Park JW et al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 2008;69:885-93.
39. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911-6.
40. Rizvi AA. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci 2009;338:310-8.